Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Current Liabilities: 2016-2025

Historic Total Current Liabilities for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $340.0 million.

  • Ultragenyx Pharmaceutical's Total Current Liabilities rose 19.30% to $340.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.0 million, marking a year-over-year increase of 19.30%. This contributed to the annual value of $344.2 million for FY2024, which is 22.72% up from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Total Current Liabilities of $340.0 million as of Q3 2025, which was up 15.95% from $293.2 million recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Total Current Liabilities ranged from a high of $344.2 million in Q4 2024 and a low of $127.0 million during Q1 2021.
  • For the 3-year period, Ultragenyx Pharmaceutical's Total Current Liabilities averaged around $279.0 million, with its median value being $280.4 million (2023).
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Total Current Liabilities crashed by 42.17% in 2021, and later soared by 73.64% in 2022.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Total Current Liabilities (Quarterly) stood at $181.4 million in 2021, then skyrocketed by 44.02% to $261.2 million in 2022, then rose by 7.36% to $280.4 million in 2023, then climbed by 22.72% to $344.2 million in 2024, then increased by 19.30% to $340.0 million in 2025.
  • Its Total Current Liabilities stands at $340.0 million for Q3 2025, versus $293.2 million for Q2 2025 and $291.7 million for Q1 2025.